<?xml version="1.0" encoding="UTF-8"?>
<ref id="B29">
 <label>29.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Slovin</surname>
    <given-names>SF</given-names>
   </name>
   <name>
    <surname>Ragupathi</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Musselli</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Fernandez</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Diani</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Verbel</surname>
    <given-names>D</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Thomsen-friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer</article-title>. 
  <source>Cancer Immunol Immunother</source>. (
  <year>2005</year>) 
  <volume>54</volume>:
  <fpage>694</fpage>â€“
  <lpage>702</lpage>. 
  <pub-id pub-id-type="doi">10.1007/s00262-004-0598-5</pub-id>
  <?supplied-pmid 15726361?>
  <pub-id pub-id-type="pmid">15726361</pub-id>
 </mixed-citation>
</ref>
